The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levitsky, H. I.
Right arrow Articles by Kwak, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levitsky, H. I.
Right arrow Articles by Kwak, L. W.

The Journal of Immunology, Vol 156, Issue 10 3858-3865, Copyright © 1996 by American Association of Immunologists

ARTICLES

Immunization with granulocyte-macrophage colony-stimulating factor- transduced, but not B7-1-transduced, lymphoma cells primes idiotype- specific T cells and generates potent systemic antitumor immunity

HI Levitsky, J Montgomery, M Ahmadzadeh, K Staveley-O'Carroll, F Guarnieri, DL Longo and LW Kwak
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Recently, genetically modified tumor cell vaccines have been described for nonhematopoietic cancers in which the relevant Ags are unknown. Several of these cell-based vaccine strategies have been shown to induce T cell-mediated systemic antitumor immunity, either by enhancing the processing and presentation of tumor Ags by host APCs or by facilitating effective Ag presentation by the tumor vaccine itself. These strategies were compared in a model B cell lymphoma, a tumor derived from APCs, which have the inherent capacity to activate Ag- specific T cells. Eradication of pre-established systemic lymphoma was achieved following immunization with lymphoma cells engineered to produce granulocyte-macrophage (GM)-CSF, and to a lesser extent cells producing IL-4, whereas vaccination with lymphoma cells transfected with the genes encoding IL-2 or B7-1 had no effect. The systemic immunity generated by GM-CSF- or IL-4-transfected lymphoma required both CD4+ and CD8+ T cells. Previous immunotherapeutic strategies for the treatment of lymphoma have focused on the generation of Ab responses targeted to the unique Ig Id as a tumor-specific Ag. Anti- idiotypic Abs were undetectable in animals vaccinated with GM-CSF- transduced lymphoma cells. In contrast, such immunization did result in the induction of Id-specific T cell responses. This is the first demonstration that T cell responses specific for a native tumor Ag are generated by GM-CSF-transduced tumor cell-based vaccination, suggesting that B cell lymphoma may be a suitable disease for genetically modified tumor vaccine strategies.


This article has been cited by other articles:


Home page
 BloodHome page
P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation
Blood, February 15, 2008; 111(4): 2112 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
G.A. Loset, E. Lunde, B. Bogen, O.H. Brekke, and I. Sandlie
Functional phage display of two murine {alpha}/{beta} T-cell receptors is strongly dependent on fusion format, mode and periplasmic folding assistance
Protein Eng. Des. Sel., October 9, 2007; (2007) gzm044v1.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Chung, H. Qin, C.-Y. Kang, S. Kim, L. W. Kwak, and C. Dong
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity
Blood, September 15, 2007; 110(6): 2013 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. Galili, K. Wigglesworth, and U. M. Abdel-Motal
Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines
J. Immunol., April 1, 2007; 178(7): 4676 - 4687.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Zhou and H. I. Levitsky
Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance
J. Immunol., February 15, 2007; 178(4): 2155 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Bertinetti, K. Zirlik, K. Heining-Mikesch, G. Ihorst, H. Dierbach, C. F. Waller, and H. Veelken
Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Cancer Res., April 15, 2006; 66(8): 4496 - 4502.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Horna, A. Cuenca, F. Cheng, J. Brayer, H.-W. Wang, I. Borrello, H. Levitsky, and E. M. Sotomayor
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
Blood, April 1, 2006; 107(7): 2871 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Huang, P.-Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S.-H. Chen
Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host
Cancer Res., January 15, 2006; 66(2): 1123 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Zhou, C. G. Drake, and H. I. Levitsky
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Blood, January 15, 2006; 107(2): 628 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. A. Prell, B. Li, J. M. Lin, M. VanRoey, and K. Jooss
Administration of IFN-{alpha} Enhances the Efficacy of a Granulocyte Macrophage Colony Stimulating Factor-Secreting Tumor Cell Vaccine
Cancer Res., March 15, 2005; 65(6): 2449 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Rettig, J. K. Ritchey, J. L. Prior, J. S. Haug, D. Piwnica-Worms, and J. F. DiPersio
Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation
J. Immunol., September 15, 2004; 173(6): 3620 - 3630.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Serafini, R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
Cancer Res., September 1, 2004; 64(17): 6337 - 6343.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. P. Pappu and P. A. Shrikant
Alteration of Cell Surface Sialylation Regulates Antigen-Induced Naive CD8+ T Cell Responses
J. Immunol., July 1, 2004; 173(1): 275 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kochling, S. A. Konig-Merediz, R. Stripecke, D. Buchwald, A. Korte, H. G. von Einsiedel, F. Sack, G. Henze, K. Seeger, B. Wittig, et al.
Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral, Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides
Clin. Cancer Res., August 1, 2003; 9(8): 3142 - 3149.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. U. Lundin, P. O. Hofgaard, H. Omholt, L. A. Munthe, A. Corthay, and B. Bogen
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
Blood, July 15, 2003; 102(2): 605 - 612.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Briones, J. M. Timmerman, D. L. Panicalli, and R. Levy
Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules
J Natl Cancer Inst, April 2, 2003; 95(7): 548 - 555.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. M. Sotomayor, I. Borrello, F.-M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky
Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
Blood, August 15, 2001; 98(4): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Teshima, N. Mach, G. R. Hill, L. Pan, S. Gillessen, G. Dranoff, and J. L. M. Ferrara
Tumor Cell Vaccine Elicits Potent Antitumor Immunity after Allogeneic T-Cell-depleted Bone Marrow Transplantation
Cancer Res., January 1, 2001; 61(1): 162 - 171.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
Z. You, X. F. Huang, J. Hester, L. Rollins, C. Rooney, and S.-Y. Chen
Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway
J. Immunol., October 15, 2000; 165(8): 4581 - 4591.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Borrello, E. M. Sotomayor, F.-M. Rattis, S. K. Cooke, L. Gu, and H. I. Levitsky
Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines
Blood, May 15, 2000; 95(10): 3011 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Graner, A. Raymond, D. Romney, L. He, L. Whitesell, and E. Katsanis
Immunoprotective Activities of Multiple Chaperone Proteins Isolated from Murine B-Cell Leukemia/Lymphoma
Clin. Cancer Res., March 1, 2000; 6(3): 909 - 915.
[Abstract] [Full Text]

Home page
 BloodHome page
F. Osterroth, A. Garbe, P. Fisch, and H. Veelken
Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
Blood, February 15, 2000; 95(4): 1342 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Dunussi-Joannopoulos, K. Runyon, J. Erickson, R. G. Schaub, R. G. Hawley, and J. P. Leonard
Vaccines With Interleukin-12-Transduced Acute Myeloid Leukemia Cells Elicit Very Potent Therapeutic and Long-Lasting Protective Immunity
Blood, December 15, 1999; 94(12): 4263 - 4273.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. M. Sotomayor, I. Borrello, E. Tubb, J. P. Allison, and H. I. Levitsky
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
PNAS, September 28, 1999; 96(20): 11476 - 11481.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Bronte, D. B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu, and N. P. Restifo
Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
J. Immunol., May 15, 1999; 162(10): 5728 - 5737.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Shtil, J. G. Turner, J. Durfee, W. S. Dalton, and H. Yu
Cytokine-Based Tumor Cell Vaccine Is Equally Effective Against Parental and Isogenic Multidrug-Resistant Myeloma Cells: The Role of Cytotoxic T Lymphocytes
Blood, March 15, 1999; 93(6): 1831 - 1837.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky
The Central Role of CD4+ T Cells in the Antitumor Immune Response
J. Exp. Med., December 21, 1998; 188(12): 2357 - 2368.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. A. Hurwitz, T. F.-Y. Yu, D. R. Leach, and J. P. Allison
CTLA-4 blockade synergizes with tumor-derived granulocyte- macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
PNAS, August 18, 1998; 95(17): 10067 - 10071.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Osterborg, Q. Yi, L. Henriksson, J. Fagerberg, S. Bergenbrant, M. Jeddi-Tehrani, U. Ruden, A.-K. Lefvert, G. Holm, and H. Mellstedt
Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex-Restricted, CD8- and CD4-Specific T-Cell Responses
Blood, April 1, 1998; 91(7): 2459 - 2466.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
PNAS, February 3, 1998; 95(3): 1178 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Dunussi-Joannopoulos, G. Dranoff, H. J. Weinstein, J. L.M. Ferrara, B. E. Bierer, and J. M. Croop
Gene Immunotherapy in Murine Acute Myeloid Leukemia: Granulocyte-Macrophage Colony-Stimulating Factor Tumor Cell Vaccines Elicit More Potent Antitumor Immunity Compared With B7 Family and Other Cytokine Vaccines
Blood, January 1, 1998; 91(1): 222 - 230.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Cohen, O. Boyer, B. Salomon, R. Onclercq, F. Charlotte, S. Bruel, G. Boisserie, and D. Klatzmann
Prevention of Graft-Versus-Host Disease in Mice Using a Suicide Gene Expressed in T Lymphocytes
Blood, June 15, 1997; 89(12): 4636 - 4645.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Schultze, M. J. Seamon, S. Michalak, J. G. Gribben, and L. M. Nadler
Autologous Tumor Infiltrating T Cells Cytotoxic for Follicular Lymphoma Cells Can Be Expanded In Vitro
Blood, May 15, 1997; 89(10): 3806 - 3816.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.